Related Experiment Video
Updated: Jul 18, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus
Yun-Mi Song1, Joohon Sung, Soonha Yang
1Department of Family Medicine, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, 50 Irwondong, Gangnamgu, Seoul, South Korea. ymsong@smc.samsung.co.kr
Insights
Hepatitis B virus (HBV) immunoprophylaxis failure in newborns can occur, particularly when mothers are HBeAg-positive or have detectable HBV DNA. Assessing these maternal factors before childbirth is crucial for identifying high-risk infants.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Perinatal transmission of Hepatitis B virus (HBV) persists despite immunoprophylaxis.
- Understanding factors contributing to immunoprophylaxis failure is essential for preventing HBV infection in newborns.
Purpose of the Study:
- To evaluate factors associated with the failure of Hepatitis B virus (HBV) immunoprophylaxis in infants born to HBsAg-seropositive mothers.
- To identify specific maternal markers that predict immunoprophylaxis failure.
Main Methods:
- A cohort of 144 infants born to HBsAg-seropositive mothers received standard HBV immunoprophylaxis (HB immune globulin and HB vaccine).
- Infants were monitored for HBsAg-seropositivity, indicating immunoprophylaxis failure.
- Maternal HBeAg and HBV DNA status were assessed.
Main Results:
- Overall immunoprophylaxis failure rate was 11.8% (17 out of 144 infants).
- Failure rates were significantly higher in infants born to mothers who were HBeAg-seropositive (21%) and HBV DNA seropositive (27%).
- Maternal HBeAg and HBV DNA positivity were significantly associated with HBV immunoprophylaxis failure.
Conclusions:
- Maternal HBeAg and HBV DNA status are critical predictors of HBV immunoprophylaxis failure in infants.
- Assessing maternal HBeAg and HBV DNA prior to childbirth can help identify infants at high risk for HBV infection.
- Targeted interventions may be necessary for high-risk neonates to improve HBV prevention efficacy.
Abstract:
In spite of adequate immunoprophylaxis, perinatal transmission of hepatitis B virus (HBV) has not been completely eliminated. This study evaluated the factors associated with the failure of HBV immunoprophylaxis. The study participants were 144 children who were born to HBsAg-seropositive mothers of known HBeAg status and they had received HB immune globulin and HB vaccine within 24 hours after birth followed by two further administrations of HB vaccine as recommended. Seventeen of the children (11.8%) suffered immunoprophylaxis failure, defined by HBsAg-seropositivity. The rate of HBV immunoprophylaxis failure was 12%, 0%, 21%, 0%, and 27% among the children born to HBsAg-seropositive, HBeAg-seronegative, HBeAg-seropositive, undetectable HBV DNA, and detectable HBV DNA mothers, respectively. The failure of HBV immunoprophylaxis was significantly associated with maternal HBeAg-seropositivity and HBV DNA seropositivity. To identify those children at high risk of HBV immunoprophylaxis failure, maternal HBeAg and HBV DNA need to be assessed prior to childbirth.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Inhibitors of Virion Maturation and Assembly
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Inhibitors of Viral Protein Synthesis
